Stada สอบถามข้อมูลเพิ่มเติมได้ที่Line OA STADA Thailand

Continue ReadingStada

Abstract 9000

Abstract 9000 Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥50%: FDA pooled analysis. Background: FDA-approved…

Continue ReadingAbstract 9000

Abstract LBA2

Abstract LBA2 Phase III assessment of topotecan & cyclophosphamide and high-dose ifosfamide in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing…

Continue ReadingAbstract LBA2

Abstract LBA4011

Abstract LBA4011 Nimotuzumab combined with gemcitabine versus gemcitabine in K-RAS wild-type locally advanced or metastatic pancreatic cancer: A prospective, randomized-controlled, double-blinded, multicenter, and phase III clinical trial. Background: Pancreatic cancer is…

Continue ReadingAbstract LBA4011

Abstract 3503

Abstract 3503 Improve Study: Randomized intermittent or continuous FOLFIRI/PANI for first-line treatment of patients (pts) with RASwt colorectal cancer Background: Continuous anti-EGFR-based FOLFIRI is a first-line standard of care in pts…

Continue ReadingAbstract 3503

Abstract 9001

Abstract 9001 Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis Background: While existing…

Continue ReadingAbstract 9001